Detalhe da pesquisa
1.
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Am J Respir Crit Care Med
; 208(4): 406-416, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37364283
2.
Reply to Gan et al., to Calzetta et al., and to Poor.
Am J Respir Crit Care Med
; 209(2): 226-228, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939377
3.
Measurement of FeNO with a portable, electrochemical analyzer using a 6-second exhalation time in 7-10-year-old children with asthma: comparison to a 10-second exhalation.
J Asthma
; 56(12): 1282-1287, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30451052
4.
Measurement of exhaled nitric oxide in young children.
Ann Allergy Asthma Immunol
; 122(3): 343-345, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30476548
5.
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Int J Chron Obstruct Pulmon Dis
; 18: 1611-1622, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37533771
6.
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
Int J Chron Obstruct Pulmon Dis
; 16: 1137-1148, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33911859
7.
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
Int J Chron Obstruct Pulmon Dis
; 15: 2199-2206, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32982212
8.
Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma.
Am J Med
; 113(1): 15-21, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12106618
9.
Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma.
Mayo Clin Proc
; 77(5): 437-45, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12004993
10.
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Pharmacoeconomics
; 20(13): 909-18, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12381242
11.
Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
Pharmacoeconomics
; 22(12): 815-25, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15294013
12.
Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study.
Int J Chron Obstruct Pulmon Dis
; 9: 745-51, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25053884
13.
Clarification of salmeterol studies.
Chest
; 123(3): 965, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12628910
14.
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves.
Ann Allergy Asthma Immunol
; 95(2): 181-9, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16136769
15.
Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age.
Ann Allergy Asthma Immunol
; 88(4): 401-9, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11991558
16.
The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis.
Allergy Asthma Proc
; 24(5): 331-7, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14619333
17.
Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
Ann Allergy Asthma Immunol
; 93(6): 581-8, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15609769
18.
Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia.
Ann Allergy Asthma Immunol
; 88(4): 385-90, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11995670
19.
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Ann Allergy Asthma Immunol
; 90(5): 536-42, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12775135
20.
Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function.
Allergy Asthma Proc
; 25(2): 115-20, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15176496